BMY240920P52000
- 2.58
- 0.000.00%
Bristol-Myers Squibb Newsroom
Goldman Sachs Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $57
Bristol-Myers Squibb Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $52
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
Bristol-Myers Squibb's KarXT Faces FDA Approval Hurdles: Analyst Issues Sell Rating Amid Labeling Concerns
Bristol-Myers Squibb (BMY): Hold Rating Justified by Mixed Growth Prospects and Pipeline Catalysts
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $51
Hold Rating on Bristol-Myers Squibb Amid Asundexian Trial Uncertainties and Milvexian Prospects
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $42
Barclays Keeps Their Sell Rating on Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb Is Maintained at Hold by Jefferies
Bristol-Myers Squibb Analyst Ratings
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $51
Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian
Bristol-Myers Squibb Analyst Ratings
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Announces Target Price $42